Association of CYP3A5*3 with Acute Lymphoblastic Leukemia susceptiveness in Chinese Han children

Abstract

Abstract: To investigate the association of CYP3A5^*3 with Acute Lymphoblastic Leukemia (ALL) susceptiveness in Chinese Han children.METHODS: CYP3A5 genotype was analyzed from 172 Chinese han children, including 52 ALL patients(27 female and 25 male) and 120 healthy controls(80 female and 92 male).Genomic DNA was extracted from blood sample, and PCR-RFLP was used to identify the polymorphism.RESULTS: This polymorphism were matched to Hardy-Weinberg equilibrium in all group.The allelic frequency of CYP3A5^*3 was 0.721 (95% CI: 0.549, 0.893) in patients while 0.758 (95% CI: 0.674, 0.842) in healthy controls. There was no significant difference existed in CYP3A5^*3 frequencies between patients and controls (P=0.275), males and females (P=0.432) in the total population.CONCLUSION: The CYP3A5^*3 variant represents a common polymorphism in Chinese healthy children and ALL, and this polymorphism is poor association with ALL susceptiveness in children.

Key words: Acute Lymphoblastic Leukemia (ALL), CYP3A5^*3, Polymorphism

CLC Number:

R968

LIU Yan, LU Xiao-tong, SHENG Qi, TIAN Huai-ping, XU A-jing, TANG Yue-nian , BU Shu-hong, LI Li-xia, ZHANG Jian. Association of CYP3A5^*3 with Acute Lymphoblastic Leukemia susceptiveness in Chinese Han children[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(1): 73-77.

References

[1] Raunio H, Husgafvel-Pursiainen K, Anttila S, et al. Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility-a review[J].Gene, 1995,159(1):113-121.
[2] Perera FP.Molecular epidemiology: insights into cancer susceptibility, risk assessment, and prevention[J].J Natl Cancer Inst,1996,88(8):496-509.
[3] Wilkinson GR. Drug metabolism and variability among patients in drug response[J]. N Engl J Med,2005,352(21):2211-2221.
[4] Lamba JK, Lin YS, Schuetz EG,et al. Genetic contribution to variable human CYP3A-mediated metabolism[J]. Adv Drug Deliv Rev,2002, 54(10):1271-1294.
[5] Wojnowski L. Genetics of the variable expression of CYP3A in humans[J]. Ther Drug Monit, 2004, 26(2):192-199.
[6] 张松波,段娟,闾四平,等.天然维生素E对CYP3A4活性影响的体内研究[J].中国临床药理学与治疗学,2010,15(8): 911-915.
[7] 李晓宇,刘皋林.CYP450酶特性及其应用研究进展[J].中国临床药理学与治疗学,2008,13(8): 942-946.
[8] Xie HG, Wood AJ, Kim RB, et al. Genetic variability in CYP3A5 and its possible consequences[J]. Pharmacogenomics, 2004,5(3):243-272.
[9] Van Schaik RH, van der Heiden IP, van den Anker JN,et al. CYP3A5 variant allele frequencies in Dutch Caucasians[J]. Clin Chem, 2002, 48(10):1668-1671.
[10] Kim KA, Park PW,Lee OJ, et al. Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean suhjects[J].Clin Pharmacol Ther, 2006, 80(6):646-656.
[11] Park JY,KimKA,Park PW,et al. Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alPrazolam in healthy subjects[J].Clin Pharmacol Ther,2006,79 (6):590-599.
[12] Bochud M,Eap CB,Elston RC,et al. Association of CYP3A5 genotypes with blood pressure and renal function in African families[J]. J Hypertens, 2006, 24(5):923-929.
[13] Quaranta S,Chevalier D,Bourgarel-Rey V,et al. Identification by single-strand conformational polymorphism analysis of known and new mutations od CYP3A5 gene in a French population[J]. Toxicol Lett, 2006,164(2):177-184.
[14] Azarpira N, Namazi S, Khalili A,et al. The investigation of allele and genotype frequencies of CYP3A5 (1^*/3^*) and P2Y12 (T744C) in Iran[J]. Mol Biol Rep,2011,38(8):4873-4877.
[15] Wang HP, Xie JJ, Zhang ZY et al. Study on polymorphisms of CYP3A5 gene and their clinical role[J]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi,2005,22(4):423-426.
[16] Huang Z, Chai YH, Cen JN,et al. Expression of CYP3A5 mRNA in children with acute leukemia[J]. Zhongguo Dang Dai Er Ke Za Zhi, 2009,11(7):549-554.
[17] Shen LJ, Chen FY, Wang T,et al.Polymorphisms of CYP3A5 gene in acute leukemia patients and their role in chemotherapy and prognosis[J]. Zhongguo Shi Yan Xue Ye Xue Za Zhi,2008,16(1):26-30.
[18] Pakakasama S,Mukda E,Sasanakul W,et al. Polymorphism s of drug-metaholizing enzymes and risk of childhood acute lymphoblastic leukemia[J]. Am J Hematol,2005,79 (3 ):202-205.
[19] Aplenc R, Glatfelter W, Han P, et al. CYP3A genotypes and treatment response in paediatric acute lymphoblastic leukaemia[J]. British Journal of Haematology, 2003,122(5):240-244.
[20] Roberts PJ, Rollins KD, Kashuba AD.The Influence of CYP3A5 Genotype on Dexamethasone Induction of CYP3A Activity in African Americans[J]. Drug Metab Dispos,2008,36(8):1465-1469.
[21] Zhang W, Yuan JJ, Kan QC,et al. Influence of CYP3A5^*3 polymorphism and interaction between CYP3A5^*3 and CYP3A4^*1G polymorphisms on post-operative fentanyl analgesia in Chinese patients undergoing gynaecological surgery[J]. Eur J Anaesthesiol,2011,28(4):245-250.
[22] Zhang J, Zhang X, Liu L,et al. Value of CYP3A5 genotyping on determining initial dosages of tacrolimus for Chinese renal transplant recipients[J]. Transplant Proc,2010,42(9):3459-3464.
[23] Borst L, Wallerek S, Dalhoff K, et al.The impact of CYP3A5*3 on risk and prognosis in childhood acute lymphoblastic lenreoomia[J]. Eur J Haematol, 2011,86(6):477-483.

Association of CYP3A5^*3 with Acute Lymphoblastic Leukemia susceptiveness in Chinese Han children

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	LI Qinghua, ZHAO Yan, ZHAO Haigang, GAO Pengfei, XU Bingxin. Value of ABCB1 G2677T gene polymorphism detection in lipid-lowering therapy with atorvastatin in patients suffered from ischemic stroke [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(6): 633-640.
[2]	ZHU Li, WEI Bing, LIAO Shi'e, ZHANG Chao, ZHENG Xiaoyu, LIU Yajun. Effects of single nucleotide polymorphism of drug metabolizing enzyme cytochrome P450 on the efficacy of inhaled cortisol hormone in asthmatic children [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 536-543.
[3]	ZHOU Jing, ZHOU Chen, LIAO Ke, QIU Ailin, DONG Weilei, GUO Zifen. Correlation between progesterone receptor G1978T polymorphism and endometrial cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 400-406.
[4]	ZHANG Zhiying, JIN Xiuhong, ZHANG Xiaoning, ZHANG Xiangfeng, LUO Qinglin, ZHANG Songlin. Clinical study of TBX21 and ADCY9 polymorphisms in the develop- ment of childhood asthma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 407-412.
[5]	LIU Lu, SHI Yufei, HE Qingfeng, XU Fengyan, WANG Kun, CAI Weimin, XIANG Xiaoqiang. Application of population modeling analysis to evaluate the impact of gene polymorphism on drug PK/PD [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1275-1282.
[6]	WANG Shuang, LIU jia, ZHANG Yueli. Associations of POR*28 polymorphisms with tacrolimus stable dose in Chinese kidney transplantation patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 991-997.
[7]	FU Hong, TIAN Lei. Individualized precision therapy for patients with ischemic stroke and hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 870-876.
[8]	CHEN Wengang, YIN Qin, ZHANG Weiwei, ZHOU Lulu, KOU Wanqing, YUAN Xiaolong. Distributions of MTHFR gene polymorphism and its correlation with blood Hcy in patients with hypertension in southern Anhui province [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 768-774.
[9]	WU Yuanzhu, LIU Jun, YANG Kui, PENG Jing, LUAN Jiajie, WEI Jun, ZHANG Dafa, SONG Shuai, YUAN Xiaolong, WANG Zhongfang, ZHANG Nianbao, XIE Dan, JIANG Peng, FAN Jie. Distribution of CYP2C9*3 and VKORC1-1639G>A gene polymorphism in Anhui Han population and their influence on the stable dose of warfarin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(6): 652-659.
[10]	CHEN Jiayin, WANG Li, WANG Lijun, TONG Gangling, MA Jie, CHEN Xijing, LU Yang. Correlation between organic cation transporter gene polymorphisms and the toxicities and clinical response of oxaliplatin [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 171-177.
[11]	ZHOU Minmin, YU Lu, HAN Chao, GU Damin, LEI Daoyun. Relationship between human cholesteryl ester transfer protein rs5882 gene polymorphism and postoperative cognitive dysfunction [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 768-774.
[12]	WANG Chunling, ZHOU Renjing, FENG Rui, WU Yanneng. Effect of adiponectin 45 T/G gene polymorphism on type 2 diabetes treated with liraglutide [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(3): 312-317.
[13]	LI Jing, Ma Lijuan, YUAN Yuan, WANG Jie, YU Changzhi, ZHAO Jun. Relationship between gene polymorphism of inhaled glucocorticosteroids budesonide and efficacy in asthma [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(11): 1250-1258.
[14]	YANG Chunyan, ZHANG Wen, WANG Peipei, PENG Jing, JIANG Jia, SONG Jing, LIU Jun, LI Yueran, YANG Kui, WANG Sheng, XU Zhenyu, LUAN Jiajie. Distribution of gene polymorphism in folate metabolism pathway and its effect on serumhomocysteine concentration [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(11): 1259-1264.
[15]	TIAN Yali, FENG Lin, ZHAO Wan, GU Min, SHEN Hanjing, CHAI Xiaoyan. Correlation of BRCA1 gene polymorphism with chemosensitivity and prognosis of metastatic esophageal squamous cell carcinoma treated with cisplatin combined with capecitabine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(10): 1118-1126.